On March 7, 2022, the Company signed an agreement with SciSparc Ltd (“SciSparc”), pursuant to which the Company and SciSparc agreed to cooperate in conducting a feasibility study using certain molecules developed by each party (the “Cooperation Agreement”). Certain of the Company’s officers and directors currently operate, manage or are engaged as officers and/or directors of SciSparc.

In June 2023, the Company entered into a research agreement with the Hebrew University of Jerusalem to evaluate its and SciSparc’s combination treatment for obesity and metabolic syndrome.

To date, the collaboration has resulted in the filing of nine patent applications. To the extent the parties determine to proceed to a commercial cooperation, they will enter into a joint venture where the parties share the economics and rights on a 50%-50% basis. To date, no determination has been made to pursue the joint venture and the development of the molecule remains in a very early stage.

For the three and nine months ended July 31, 2026, the Company incurred research and development expenses conducted within the framework of the Cooperation Agreement in the amount of $35,309 and $157,124, respectively (three and nine months ended July 31, 2025- $39,270 and $85,779 respectively). As of July 31, 2026, $440,904 is owed to the Company by SciSparc (October 31, 2025 - $286,488).